92 related articles for article (PubMed ID: 12516542)
1. Blockade of CD86 in BALB/c mice infected with Leishmania major does not prevent the expansion of low avidity T cells.
Moro M; Filippi C; Gallard A; Malherbe L; Foucras G; Akiba H; Yagita H; Guéry JC; Glaichenhaus N
Eur J Immunol; 2002 Dec; 32(12):3566-75. PubMed ID: 12516542
[TBL] [Abstract][Full Text] [Related]
2. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
[TBL] [Abstract][Full Text] [Related]
3. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB / c mice.
Maillard I; Launois P; Himmelrich H; Acha-Orbea H; Diggelmann H; Locksley RM; Louis JA
Eur J Immunol; 2001 Apr; 31(4):1288-96. PubMed ID: 11298356
[TBL] [Abstract][Full Text] [Related]
4. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
5. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
6. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
[TBL] [Abstract][Full Text] [Related]
7. LACK-reactive CD4+ T cells require autocrine IL-2 to mediate susceptibility to Leishmania major.
Gumy A; Aseffa A; Rachinel N; Breton M; Otten L; Tacchini-Cottier F; Röcken M; Doyen N; Acha-Orbea H; Locksley RM; MacDonald HR; Launois P; Louis J
Eur J Immunol; 2006 Jun; 36(6):1465-73. PubMed ID: 16637008
[TBL] [Abstract][Full Text] [Related]
8. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.
Flórido M; Borges M; Yagita H; Appelberg R
J Leukoc Biol; 2004 Nov; 76(5):1039-46. PubMed ID: 15316035
[TBL] [Abstract][Full Text] [Related]
9. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
10. Control of Leishmania major by a monoclonal alpha beta T cell repertoire.
Reiner SL; Fowell DJ; Moskowitz NH; Swier K; Brown DR; Brown CR; Turck CW; Scott PA; Killeen N; Locksley RM
J Immunol; 1998 Jan; 160(2):884-9. PubMed ID: 9551925
[TBL] [Abstract][Full Text] [Related]
11. Blockade of CD86 signaling facilitates a Th2 bias at the maternal-fetal interface and expands peripheral CD4+CD25+ regulatory T cells to rescue abortion-prone fetuses.
Zhu XY; Zhou YH; Wang MY; Jin LP; Yuan MM; Li DJ
Biol Reprod; 2005 Feb; 72(2):338-45. PubMed ID: 15456701
[TBL] [Abstract][Full Text] [Related]
12. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
Gramaglia I; Weinberg AD; Lemon M; Croft M
J Immunol; 1998 Dec; 161(12):6510-7. PubMed ID: 9862675
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
16. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
17. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
[TBL] [Abstract][Full Text] [Related]
18. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.
Akiba H; Miyahira Y; Atsuta M; Takeda K; Nohara C; Futagawa T; Matsuda H; Aoki T; Yagita H; Okumura K
J Exp Med; 2000 Jan; 191(2):375-80. PubMed ID: 10637281
[TBL] [Abstract][Full Text] [Related]
19. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
[TBL] [Abstract][Full Text] [Related]
20. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
